ArticleBMC infectious diseases2025
Re-emergence of Mycoplasma pneumoniae before and after COVID-19 pandemic in Germany.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neutrophil-to-lymphocyte ratio for predicting disease severity and outcomes in children with Mycoplasma pneumoniae pneumonia: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Reporting macrolide-resistantJournal of clinical microbiology · 2026Review
- Multi-Omics Profiling Identifies Immune-Metabolic Signatures and Gut Microbial Biomarkers in a Murine Model ofBiology · 2026Article
- Etiological characterization of acute respiratory tract infections and associated co-infections using Biofire respiratory 2.1 Plus panel.BMC infectious diseases · 2026Article
- Post-pandemic resurgence of Mycoplasma pneumoniae and its emerging link with Rhinovirus in children.Infection · 2026Article
- Upsurge of Chlamydia pneumoniae respiratory tract infections in 2024/2025 in Southern Germany.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Genomic surveillance of the pneumonia outbreak caused byFrontiers in cellular and infection microbiology · 2026Article
- Impact of COVID-19 on the epidemiological features of mycoplasma pneumoniae infection in children with community-acquired pneumonia in Ganzhou, China.Frontiers in immunology · 2026Article
- Mycoplasma pneumoniae in hospitalised children in the post-COVID era: clinical outcomes from a Turkish multicenter cohort.European journal of pediatrics · 2025Article
- Changes inMicrobiology spectrum · 2025Article
- Characteristics and risk factors for outcomes in patients withInfectious Disease Modelling · 2025Article
- A comparison of diagnostic and therapeutic approaches for Mycoplasma pneumoniae pneumonia in children and adults, during the post-COVID-19 pandemic era.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma pneumoniae (M. pneumoniae) is a common pathogen of community-acquired pneumonia (CAP). Epidemics occur every 3-7 years especially in pediatric patients. We collected data from a large laboratory network in Germany to define the epidemiological dynamics in the pre- and post-COVID-19 pandemic period.
methodsIn this retrospective cohort study we included all patients that obtained targeted or multiplex PCR for M. pneumoniae from nasopharyngeal swabs, sputum or bronchoalveolar fluids from 2015 to 2024. Demographic data (age, sex, place of residence, in- or outpatient status) were compared between M. pneumoniae positive and negative patients and co-infections with bacterial or viral pathogens analyzed.
resultsWe screened 38,204 patients for M. pneumoniae. We identified 1448 cases (3.8%) of M. pneumoniae (48.8% females). Pediatric patients ≤ 18 years represented 75.7% of M. pneumoniae patients and 2.3% were ≥ 60 years. Incidence of M. pneumoniae increased in fourth quartile 2015 (16.2%), second quartile 2018 (14.8%) and fourth quartile 2023 (13.4%). No cases were detected during COVID-19 pandemic 2021. Young age (aOR 0.98 95%-CI 0.97-0.98), outpatient status (aOR 0.56 95%-CI 0.43-0.71) and year of testing (OR dependent on year of testing) were predictors of M. pneumoniae detection in multivariate analysis (p < 0.001). We observed a significant increase in outpatients with M. pneumoniae after COVID-19 pandemic (86.7 vs. 96.5%, p = < 0.001, aOR 0.25, 95% CI 0.15-0.4).
conclusionsEmpirical treatment of CAP patients often does not include coverage of M. pneumoniae. A more thorough implementation of available surveillance data into clinical routine, respective therapies could be adapted more quickly during epidemic outbreaks of M. pneumoniae infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.